State Street
SKYE icon

State Street’s Skye Bioscience SKYE Stock Holding History

State Street’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2K Sell
9,229
-187
-2% -$1.18K ﹤0.01% 4052
2026
Q1 		$46.3K Hold
9,416
– – ﹤0.01% 4139
2025
Q4 		$56.5K Hold
9,416
– – ﹤0.01% 4133
2025
Q3 		$296K Buy
9,416
+1,078
+13% +$32.6K ﹤0.01% 3793
2025
Q2 		$279K Sell
8,338
-37,901
-82% -$628K ﹤0.01% 3747
2025
Q1 		$588K Sell
46,239
-574
-1% -$12.5K ﹤0.01% 3554
2024
Q4 		$1.06M Buy
46,813
+2,537
+6% +$84.8K ﹤0.01% 3481
2024
Q3 		$1.38M Buy
44,276
+2,900
+7% +$130K ﹤0.01% 3420
2024
Q2 		$2.65M Buy
+41,376
New +$3.93M ﹤0.01% 3204

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street's SKYE Position: Q2 2026 in Review

State Street reduced its Skye Bioscience (SKYE) stake by 2% in Q2 2026, selling an estimated $1.18K and leaving 9,229 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4052.

State Street first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.65M in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • State Street held 9,229 shares of Skye Bioscience worth $51.2K as of Q2 2026.
  • State Street sold 187 Skye Bioscience shares in Q2 2026, an estimated $1.18K.
  • Skye Bioscience made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4052 holding.
  • State Street first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • State Street's Skye Bioscience position peaked at $2.65M in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.